-
JAMA Oncol: Cost-effectiveness ratio for prostate cancer screening with MRI+ biopsy
Time of Update: 2022-11-25
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.
-
Science sub-journal discovered drug targets for the treatment of rare, deadly neurocarcinoma MPNST
Time of Update: 2022-11-15
essaySingle-cell multi-omics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy Image: Using Slingshot to infer the trajectory of tumor cell states from NF to MPNST.
Image credit: Cincinnati Center for Children and Scientific ProgressImage: Using Slingshot to infer the trajectory of tumor cell states from NF to MPNST.
-
Cancer Vaccines: The Next Frontier of Immunotherapy
Time of Update: 2022-09-07
1038/s43018-022-00418-6Figure 1: Types of cancer vaccinesTumor-specific antigens (TSAs) are mainly divided into two broad categories, including new epitopes caused by viral antigens and non-synonymous cell mutations, and two types of tumor-associated antigens (TAA), including tissue-specific antigens and development-specific antigens.
-
Circular RNA circCCNB1 inhibits migration and invasion of nasopharyngeal carcinoma
Time of Update: 2022-08-10
Fuyan Wang (Key Laboratory of Tumorgenesis and Tumor Invasion of the Ministry of Education, Institute of Cancer Research, Central South University) found that the oncogene CCBN1 The circular RNA circCCNB1 was down-regulated in nasopharyngeal carcinoma and inhibited the migration and invasion of nasopharyngeal carcinoma cells .
-
Anti-angiogenesis + immunotherapy succeeded again, new standard of treatment for advanced endometrial cancer NEJM
Time of Update: 2022-02-21
The trial compared the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy in patients with advanced endometrial cancer whose tumors had progressed after at least one platinum-based chemotherapy .
-
Express targeting antigens in cancer cells, Boehringer Ingelheim received new immunotherapy technology
Time of Update: 2021-10-01
Abexxa focuses on the development of innovative immunotherapies around the intracellular antigens presented by atypical major histocompatibility complex (MHC) class I molecules on cancer cells to directly kill tumors or mediate tumor death through immune regulation .
-
Lung Cancer: Real-world studies to evaluate the efficacy of immunotherapy in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC
Time of Update: 2021-08-01
For metastatic non-small cell lung cancer ( NSCLC ) with negative EGFR and ALK mutations , single-agent immunotherapy or combined chemotherapy is currently recommended as the first-line treatment .
-
Leadstar Biosciences and Baitu Biosciences jointly promote the precise development and scientific research transformation of innovative oncology drugs
Time of Update: 2021-07-01
Qiang Xu, founder and CEO of Leadstar Biotech, was invited to deliver a keynote speech "Best-In-Class Real World Data Solution for Chinese Cancer Patients" at the "More Possibilities of Biocomputing-Innovative Enterprise DEMO" on May 11th.
-
The latest research on the two most common cancer-causing mutations found a new treatment strategy for the "king of cancer
Time of Update: 2021-05-23
A few days ago, a research team from the MD Anderson Cancer Center in the United States published a study on Cancer Discovery showing that the interaction between TP53 gene mutations and KRAS oncogenic mutations can stimulate a wide range of signaling pathways to drive pancreatic cancer metastasis .
-
Genting Xinyao Goshatuomab was awarded Orphan Drug Designation by MFDS in South Korea
Time of Update: 2021-05-22
Genting Shinyao announced today that Gosartuzumab has obtained orphan drug designation granted by South Korea’s MFDS, which is used to treat locally unresectable advanced or metastatic triple-negative breasts that have received at least two lines or more of previous treatment.
ADC drugs for adult cancer patients are still in the research stage in South Korea.
-
Prof. Cui Chuanliang: Interpretation of the key points of the 2021 CSCO Urothelial Carcinoma Diagnosis and Treatment Guidelines Update
Time of Update: 2021-05-22
In the first-line treatment of the new CSCO guidelines for urothelial cancer, for patients with locally advanced or metastatic urothelial cancer that are not suitable for cisplatin, the level III recommendation still retains atezizumab (class 2A evidence) and pembrolizumab Monoclonal antibody (Class 2A evidence).
-
Br J Cancer: Mandard grade is high: it does not mean that esophageal adenocarcinoma does not respond to chemotherapy
Time of Update: 2021-03-30
Kaplan-Meier analysis of patients' relapse-free survival rateAll in all, the results of the study show that in patients with poor Mandard grade, complete lymph node response can significantly improve patient outcomes.
In patients with poor Mandard grade, complete lymph node response can significantly improve the patient's outcome.
-
GSK published positive data on dostarlimab in dMMR solid tumors
Time of Update: 2021-01-23
On January 16, GlaxoSmithKline (GSK) announced the latest data from the GARNET Study F Queue, which is used primarily to assess the role of dostarimab in non-endometrial advanced solid tumors with mismatch repair defects (dMMR), which was presented at the 2021 American Society of Clinical Oncology Gastrointestinal Oncology Symposium (ASCO GI).
-
Health care negotiations close to PD-1 fierce competition Hengrui, Baiji Shenzhou, Junshi... Who are you Pick
Time of Update: 2021-01-10
From the domestic 4 PD-1 sales, Daboshu into health insurance, sales revenue relative to Junshi, Baiji Shenzhou PD-1 (Note: Bazean in March this year officially listed sales) is still considerable, but Hengrui's PD-1 product sales are not small, although Q2 to Q3 sales are not disclosed, but the industry expects Hengrui PD-1 single resistance sales revenue of about 3 billion yuan in the first three quarters.
-
Nature: CRISPR found 182 potential immunotherapy targets to uncover immune escapes for cancer cells
Time of Update: 2020-10-16
researchers say these are due to the "core cancer intrinsic immune evasion gene." through CRISPR knock-out screening of six different cancer cell lines, the researchers found that many of them were associated with the signaling pathline of the regulator interferon γ (IFN) by analyzing the key role of autophagy signaling pathps in immune escape.
